Clinical Trials

MBQ Pharma announces the First-in-Human Dose of MBQ-167 for Advanced Breast Cancer in a Phase 1 Clinical Trial in Puerto Rico with the dual targeted Rac/Cdc42 inhibitor

This article is reproduced by CienciaPR with permission from the original source.

CienciaPR Contribution: 

No

- MBQ-167 is a first-in-class small molecule and dual targeted inhibitor of over-expression of two proteins (Rac and Cdc42) that enable cancer metastasis and increased resistance to other anti-
cancer agents.

- 90% of cancer-related deaths are related to cancer metastasis and MBQ-167 is being evaluated in
this first human clinical trial to determine the best dose to evaluate this investigational drug in
future studies to determine its safety and efficacy for reducing this terrible outcome.

Tags: 

WORKING TOWARDS A CLINICAL TRIAL CULTURE IN PUERTO RICO

Natasha De Leon Rodriguez's picture

Working towards a clinical trial culture in Puerto Rico

By: Natasha DeLeon-Rodriguez, Ph.D.

Doctors and researchers work towards developing new drugs, new procedures to cure, detect, prevent or treat diseases. But the people, families and patients, have put their trust and life by joining the clinical trials needed to determine if these drugs or procedures worked. The combination of both parts, doctors and patients, are crucial to advance medicine.

Cursos cortos de verano en el Departamento de Bioestadísticas, Universidad de Washington

Mónica Ivelisse Feliú-Mójer's picture

The Summer Institutes consist of a series of short workshops conducted by experts in the subject fields and designed to introduce participants to modern issues and challenges in biostatistics, genetics, infectious diseases, epidemiology and clinical trials. Prerequisites are minimal, and the modular nature of the Institutes enables participants to design a program best suited to their backgrounds and interests.

Rating: 

0

Forums: 

Tags: 

Subscribe to Clinical Trials